Clinical Spectrum of Hemolytic Anemia Associated with Glucose-6-Phosphate Dehydrogenase Deficiency

Burka, Edward R.; Weaver, Zebulon; Marks, Paul A.

doi:10.7326/0003-4819-64-4-817

Search citation statements

Order By: Relevance

Paper Sections

Select...

Infection-induced Hemolysis1

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1967

2009

Publication Types

Select...

Article10

Relationship

Self Cite0

Independent10

Authors

Journals

Cited by 131 publications

(34 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This association has been reported in Negroes (Burka, Weaver, and Marks, 1966;Salen et al, 1966), Mediterranean people (Choremis et al, 1966), and Chinese (Wong, 1966). The difficulty is to know whether viral hepatitis or drugs given to these patients was responsible since many drugs have been incriminated (WHO Report, 1967).…”

supporting

confidence: 59%

Double heterozygosity for glucose-6-phosphate dehydrogenase deficiency.

Chan¹,

Lai²

1971

Journal of Medical Genetics

View full text Add to dashboard Cite

supporting

confidence: 59%

Double heterozygosity for glucose-6-phosphate dehydrogenase deficiency.

Chan¹,

Lai²

1971

Journal of Medical Genetics

View full text Add to dashboard Cite

“…Indeed, a decade after the discovery of G6PD deficiency as the cause of drug-induced hemolysis, a survey of 73 episodes of hemolysis in a hospital in New York City suggested that infection was the most common precipitating factor of hemolytic anemia among G6PD-deficient patients. 21 …”

Section: Infection-induced Hemolysismentioning

confidence: 99%

Glucose-6-phosphate dehydrogenase deficiency: a historical perspective

Beutler

2008

Blood

298

223

View full text Add to dashboard Cite

Glucose-6-phosphate dehydrogenase deficiency serves as a prototype of the many human enzyme deficiencies that are now known. Since its discovery more than 50 years ago, the high prevalence of the defect and the easy accessibility of the cells that manifest it have made it a favorite tool of biochemists, epidemiologists, geneticists, and molecular biologists as well as clinicians. In this brief historical review, we trace the discovery of this defect, its clinical manifestations, detection, population genetics, and molecular biology. (Blood. 2008;111:16-24)

show abstract

“…Patients with glucose-6-phosphate dehydrogenase deficiency of red blood cells (G6PD RBC)1 may develop hemolytic anemia during acute infection (1)(2)(3)(4) Received for publication 22 February 1971 and in revised form 26 April 1971. 'Abbreviations used in this paper: CGD, chronic granulomatous disease; G6PD, glucose-6-phosphate dehydrogenase; GSH, reduced glutathione; HMPS, hexose monophosphate shunt; KRP, Krebs-Ringer phosphate buffer; PMN, polymorphonuclear leukocytes; RBC, red blood cells.…”

Section: Introductionmentioning

confidence: 99%